Evidence map›Paper›PMID 33767355›Full record

ArticleProstate cancer and prostatic diseases2021

Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer.

A M Algotar, C H Hsu, H-H Chow, S T Dougherty, H M Babiker, D G Marrero, I Abraham, R Kumar, J A Ligibel, K S Courneya and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

A M AlgotarDepartment of Family and Community Medicine, University of Arizona, Tucson, AZ, USA. algotar@email.arizona.edu.
C H HsuThe University of Arizona Cancer Center, Tucson, AZ, USA.
H-H ChowThe University of Arizona Cancer Center, Tucson, AZ, USA.
S T DoughertyThe University of Arizona Cancer Center, Tucson, AZ, USA.
H M BabikerThe University of Arizona Cancer Center, Tucson, AZ, USA.
D G MarreroDepartment of Health Promotion Science, Mel and Enid College of Public Health, University of Arizona, Tucson, AZ, USA.
I AbrahamDepartment of Family and Community Medicine, University of Arizona, Tucson, AZ, USA.
R KumarRadiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
J A LigibelDana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
K S CourneyaFaculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada.
T E SmithDepartment of Family and Community Medicine, University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0001-9116-3312
P A JonesDepartment of Epidemiology and Biostatistics, Mel and Enid College of Public Health, University of Arizona, Tucson, AZ, USA.
J N LopezDepartment of Family and Community Medicine, University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-3479-0317
G NiemiroDepartment of Pediatrics, University of Arizona, Tucson, AZ, USA.
S RamakumarArizona Institute of Urology, Tucson, AZ, USA.
R D HoyArizona Institute of Urology, Tucson, AZ, USA.
C MackArizona Oncology, Tucson, AZ, USA.
C A ThomsonThe University of Arizona Cancer Center, Tucson, AZ, USA.ORCID http://orcid.org/0000-0003-3645-7048
University of Arizona · USTucson Orthopaedic Institute · USArizona Oncology · USHarvard University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAndrogen deprivation therapy (ADT) for prostate cancer is associated with adverse effects, such as obesity and metabolic syndrome, which increase cardiovascular risk, the most common cause of non-cancer mortality in men diagnosed with prostate cancer. The Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) was created to determine the feasibility of conducing a comprehensive lifestyle modification intervention in men on ADT for prostate cancer and determine its early efficacy in reducing obesity and metabolic syndrome.

methodsA single-arm, open-label clinical trial was conducted by recruiting 31 men diagnosed with prostate cancer and exposed to ADT within the last 5 years. A multicomponent lifestyle modification program was delivered weekly for 16 weeks by a trained health coach. This was followed by 8 weeks of passive follow-up resulting in a total trial duration of 24 weeks. Feasibility was determined by calculating study recruitment, retention, and adherence rates. Weight and components of metabolic syndrome (waist circumference, triglycerides (TG), high-density lipoprotein (HDL), serum glucose, and blood pressure (BP)) were measured at baseline, 12, and 24 weeks.

resultsRecruitment, retention, and adherence rates were 47.1%, 90.3%, and 100%, respectively. Statistically significant improvements were noted between baseline and end of study measurements for weight (206.3 vs. 191.3 lbs, p < 0.001), waist (41.3 vs. 38.8 inches, p < 0.001), systolic BP (144.1 vs. 133.4 mm of Hg, p = 0.014), diastolic BP (83.3 vs. 76.2 mm of Hg, p = 0.0056), TG (146.0 vs. 113.8 mg/dl, p = 0.022), HDL (51.1 vs. 55.0 mg/dl, p = 0.012), and serum glucose (114.0 vs. 103.2 mg/dl, p = 0.013).

conclusionCLIPP demonstrates feasibility and early efficacy of a multicomponent lifestyle modification intervention toward addressing obesity as well as components of metabolic syndrome in men on ADT for prostate cancer. This study provides strong preliminary data to develop future clinical trials in this population.

Indexed as

Body WeightLife StyleAdultAgedAndrogen AntagonistsFeasibility StudiesFollow-Up StudiesHumansMaleMetabolic SyndromeMiddle AgedObesityPrognosisProstatic NeoplasmsAndrogen Antagonists

Identifiers

PMID33767355
OpenAlexW3137551365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.